Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 5;8(7):e0487.
doi: 10.1097/HC9.0000000000000487. eCollection 2024 Jul 1.

Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction-associated steatotic liver disease

David E Kaplan  1   2 , Craig C Teerlink  3   4 , Tae-Hwi Schwantes-An  5 , Trina M Norden-Krichmar  6   7 , Scott L DuVall  3   4 , Timothy R Morgan  6   8 , Philip S Tsao  9   10 , Benjamin F Voight  1   11   12 , Julie A Lynch  3   4 , Marijana Vujković  1   2   13 , Kyong-Mi Chang  1   2
Affiliations

Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction-associated steatotic liver disease

David E Kaplan et al. Hepatol Commun. .

Abstract

Background: Fibrosis-4 (FIB4) is a recommended noninvasive test to assess hepatic fibrosis among patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we used FIB4 trajectory over time (ie, "slope" of FIB4) as a surrogate marker of liver fibrosis progression and examined if FIB4 slope is associated with clinical and genetic factors among individuals with clinically defined MASLD within the Million Veteran Program Cohort.

Methods: In this retrospective cohort study, FIB4 slopes were estimated through linear regression for participants with clinically defined MASLD and FIB4 <2.67 at baseline. FIB4 slope was correlated with demographic parameters and clinical outcomes using logistic regression and Cox proportional hazard models. FIB4 slope as a quantitative phenotype was used in a genome-wide association analysis in ancestry-specific analysis and multiancestry meta-analysis using METAL.

Results: FIB4 slopes, generated from 98,361 subjects with MASLD (16,045 African, 74,320 European, and 7996 Hispanic), showed significant associations with sex, ancestry, and cardiometabolic risk factors (p < 0.05). FIB4 slopes also correlated strongly with hepatic outcomes and were independently associated with time to cirrhosis. Five genetic loci showed genome-wide significant associations (p < 5 × 10-8) with FIB4 slope among European ancestry subjects, including 2 known (PNPLA3 and TM6SF2) and 3 novel loci (TERT 5.1 × 10-11; LINC01088, 3.9 × 10-8; and MRC1, 2.9 × 10-9).

Conclusions: Linear trajectories of FIB4 correlated significantly with time to progression to cirrhosis, with liver-related outcomes among individuals with MASLD and with known and novel genetic loci. FIB4 slope may be useful as a surrogate measure of fibrosis progression.

PubMed Disclaimer

Conflict of interest statement

Julie A. Lynch received grants from Alnylam, Astellas, AstraZeneca, Biodesix, Celgene, Cerner Enviza, GlaxoSmithKline, IQVIA, Janssen, Kantar Health, Myriad Genetic Laboratories, Novartis, and Parexel. Scott L. DuVall received grants from Alnylam, Astellas, AstraZeneca, Biodesix, Celgene, Cerner Enviza, GlaxoSmithKline, IQVIA, Janssen, Kantar Health, Myriad Genetic Laboratories, Novartis, and Parexel. David E. Kaplan advises and received grants from AstraZeneca and Roche Genentech. He received grants from Bausch, Exact, and Glycotest. Tae-Hwi Scwahtes-An consults for Target RWE. Kyong-Mi Chang consults for GlaxoSmithKline. He advises Virion. The remaining authors have no conflicts to report.

Figures

None
Graphical abstract
FIGURE 1
FIGURE 1
FIB4 slopes evolve linearly in MASLD. (A) Representative dot plots of FIB4 values over years of clinical follow-up. Slope values derived from linear models are represented by a solid red line and reported in the top right. FIB4 slopes using only first 5 years of data are shown in the red dotted lines. (B) Distribution of FIB4 slope values. (C) QQ plot for distribution showing normality. (D) Distribution of FIB4 slopes by FIB4 baseline <1.3 or 1.3–2.67. (E) Distribution of FIB4 slope values by genetic ancestry. Abbreviations: FIB4, Fibrosis-4; MASLD, metabolic dysfunction–associated steatotic liver disease.
FIGURE 2
FIGURE 2
Association of FIB4 slopes and clinical outcomes. (A) LOWESS curves showing HR of outcome relative to FIB4 slope. (B) Kaplan-Meier curves of time to clinical outcomes stratified by FIB4 value above or below 0.082 based on the Youden cutpoint. Abbreviation: FIB4, Fibrosis-4.
FIGURE 3
FIGURE 3
Contribution of FIB4 slope to the clinical prediction of cirrhosis. (A) AUROC curves for prediction of cirrhosis for FIB4 slope (dotted), clinical model (dashed), and combined model (solid). (B) Calibration curves for models shown in (A). (C) Decision curve analysis for models shown in (A). (D) Percentage of χ2 of Cox models explained by each predictive variable. Abbreviation: FIB4, Fibrosis-4.
FIGURE 4
FIGURE 4
Manhattan plot for multiancestry GWAS meta-analysis of FIB4 slope in individuals with MASLD. Significant SNPs on chromosomes 4, 5, 10, 19, and 22 were observed at a threshold p value of 5 × 10−8. A QQ plot is embedded. Abbreviations: FIB4, Fibrosis-4; GWAS, genome-wide association study; MASLD, metabolic dysfunction–associated steatotic liver disease.
None
None
None
None
None
None
None
None
None
None
None
None
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. - PubMed
    1. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–649. - PubMed
    1. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. . Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.e10. - PMC - PubMed
    1. Simon TG, Roelstraete B, Sharma R, Khalili H, Hagström H, Ludvigsson JF. Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: A population-based cohort study. Hepatology. 2021;74:2410–2423. - PMC - PubMed
    1. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643–54; e1–e9; quiz e39–e40. - PMC - PubMed

Publication types